BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 34250420)

  • 1. ctDNA MRD Detection and Personalized Oncogenomic Analysis in Oligometastatic Colorectal Cancer From Plasma and Urine.
    Pellini B; Pejovic N; Feng W; Earland N; Harris PK; Usmani A; Szymanski JJ; Qaium F; Mudd J; Petty M; Jiang Y; Singh A; Maher CA; Henke LE; Park H; Ciorba MA; Kim H; Mutch MG; Pedersen KS; Tan BR; Hawkins WG; Fields RC; Chaudhuri AA
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer.
    Parikh AR; Van Seventer EE; Siravegna G; Hartwig AV; Jaimovich A; He Y; Kanter K; Fish MG; Fosbenner KD; Miao B; Phillips S; Carmichael JH; Sharma N; Jarnagin J; Baiev I; Shah YS; Fetter IJ; Shahzade HA; Allen JN; Blaszkowsky LS; Clark JW; Dubois JS; Franses JW; Giantonio BJ; Goyal L; Klempner SJ; Nipp RD; Roeland EJ; Ryan DP; Weekes CD; Wo JY; Hong TS; Bordeianou L; Ferrone CR; Qadan M; Kunitake H; Berger D; Ricciardi R; Cusack JC; Raymond VM; Talasaz A; Boland GM; Corcoran RB
    Clin Cancer Res; 2021 Oct; 27(20):5586-5594. PubMed ID: 33926918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic monitoring of circulating tumor DNA to predict prognosis and efficacy of adjuvant chemotherapy after resection of colorectal liver metastases.
    Wang DS; Yang H; Liu XY; Chen ZG; Wang Y; Fong WP; Hu MT; Zheng YC; Zheng Y; Li BK; Yuan YF; Chen G; Pan ZZ; Song L; Li YH; Xu RH
    Theranostics; 2021; 11(14):7018-7028. PubMed ID: 34093868
    [No Abstract]   [Full Text] [Related]  

  • 5. Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study.
    Chauhan PS; Chen K; Babbra RK; Feng W; Pejovic N; Nallicheri A; Harris PK; Dienstbach K; Atkocius A; Maguire L; Qaium F; Szymanski JJ; Baumann BC; Ding L; Cao D; Reimers MA; Kim EH; Smith ZL; Arora VK; Chaudhuri AA
    PLoS Med; 2021 Aug; 18(8):e1003732. PubMed ID: 34464379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive Genomic Profiling (CGP)-Informed Personalized Molecular Residual Disease (MRD) Detection: An Exploratory Analysis from the PREDATOR Study of Metastatic Colorectal Cancer (mCRC) Patients Undergoing Surgical Resection.
    Lonardi S; Nimeiri H; Xu C; Zollinger DR; Madison RW; Fine AD; Gjoerup O; Rasola C; Angerilli V; Sharma S; Wu HT; Palsuledesai CC; Malhotra M; Aleshin A; Loupakis F; Renkonen E; Hegde P; Fassan M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
    Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer.
    McDonald BR; Contente-Cuomo T; Sammut SJ; Odenheimer-Bergman A; Ernst B; Perdigones N; Chin SF; Farooq M; Mejia R; Cronin PA; Anderson KS; Kosiorek HE; Northfelt DW; McCullough AE; Patel BK; Weitzel JN; Slavin TP; Caldas C; Pockaj BA; Murtaza M
    Sci Transl Med; 2019 Aug; 11(504):. PubMed ID: 31391323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
    Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
    Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer.
    Kasi PM; Sawyer S; Guilford J; Munro M; Ellers S; Wulff J; Hook N; Krinshpun S; Koyen Malashevich A; Malhotra M; Rodriguez A; Moshkevich S; Grothey A; Kopetz S; Billings P; Aleshin A
    BMJ Open; 2021 Sep; 11(9):e047831. PubMed ID: 34561256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer.
    Ryoo SB; Heo S; Lim Y; Lee W; Cho SH; Ahn J; Kang JK; Kim SY; Kim HP; Bang D; Kang SB; Yu CS; Oh ST; Park JW; Jeong SY; Kim YJ; Park KJ; Han SW; Kim TY
    Br J Cancer; 2023 Aug; 129(2):374-381. PubMed ID: 37280413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A ctDNA-driven multidisciplinary treatment strategy for resectable colorectal cancer -what surgical oncologists should know.
    Kataoka K; Yamada T; Taniguchi H; Ikeda M; Yamazaki K; Kanemitsu Y
    Eur J Surg Oncol; 2022 Jan; 48(1):1-2. PubMed ID: 34635368
    [No Abstract]   [Full Text] [Related]  

  • 13. Circulating tumor DNA analysis predicts recurrence and avoids unnecessary adjuvant chemotherapy in I-IV colorectal cancer.
    Fan W; Xia Z; Chen R; Lin D; Li F; Zheng Y; Luo J; Xiong Y; Yu P; Gao W; Gong Y; Zhang F; Zhang S; Li L
    Ther Adv Med Oncol; 2024; 16():17588359231220607. PubMed ID: 38282662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases.
    Loupakis F; Sharma S; Derouazi M; Murgioni S; Biason P; Rizzato MD; Rasola C; Renner D; Shchegrova S; Koyen Malashevich A; Malhotra M; Sethi H; Zimmermann BG; Aleshin A; Moshkevich S; Billings PR; Sedgwick JD; Schirripa M; Munari G; Cillo U; Pilati P; Dei Tos AP; Zagonel V; Lonardi S; Fassan M
    JCO Precis Oncol; 2021 Jul; 5():. PubMed ID: 34327297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.
    Honoré N; van Marcke C; Galot R; Helaers R; Ambroise J; van Maanen A; Mendola A; Dahou H; Marbaix E; Van Eeckhout P; Longton E; Magremanne M; Schmitz S; Limaye N; Machiels JP
    Ann Oncol; 2023 Dec; 34(12):1175-1186. PubMed ID: 37879442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
    Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
    Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
    Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
    Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer.
    Emiloju OE; Storandt M; Zemla T; Tran N; Jethwa K; Mahipal A; Mitchell J; Thiels C; Mathis K; McWilliams R; Hubbard J; Sinicrope F; Shi Q; Jin Z
    JCO Precis Oncol; 2024 Jan; 8():e2300127. PubMed ID: 38237099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA).
    Chin RI; Chen K; Usmani A; Chua C; Harris PK; Binkley MS; Azad TD; Dudley JC; Chaudhuri AA
    Mol Diagn Ther; 2019 Jun; 23(3):311-331. PubMed ID: 30941670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics.
    Choi IS; Kato S; Fanta PT; Leichman L; Okamura R; Raymond VM; Lanman RB; Lippman SM; Kurzrock R
    Mol Cancer Ther; 2019 Oct; 18(10):1852-1862. PubMed ID: 31320401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.